Senores Pharmaceuticals Share Price Target 2025, 2026, 2030, 2050
Senores Pharmaceuticals Ltd is an Indian company that makes and sells medicines. It develops different types of drugs, including prescription and over-the-counter products, to help treat various health conditions. The company also focus on improving existing drugs or creating new ones.
What is Senores Pharmaceuticals Ltd
Contents
- 1 What is Senores Pharmaceuticals Ltd
- 2 Senores IPO Details
- 3 share price Target Tomorrow
- 4 Senores share price Target 2025
- 5 Senores share price Target 2026
- 6 Senores share price Target 2030
- 7 share price Target 2040
- 8 share price Target 2050
- 9 Should I buy Senores stock?
- 10 Senores Pharmaceuticals Ltd earning results (Financials)
- 11 Is Senore stock good to buy? (Bull case & bear case)
- 12 Senores IPO Promoter Holding
- 13 Objects of the Issue (Senores IPO Objectives)
- 14 Senores IPO GMP
- 15 Conclusion
- 16 FAQs
Senores Pharmaceuticals Ltd. is an Indian company in Ahmedabad established in 2017. It makes and develops medicines, mainly for markets like the United States, Canada, and the United Kingdom. The company works in several medical areas and produces different types of medicines. It also works with other companies to source certain products that meet the specific needs of its customers and marketing partners. The company uses its facility in Atlanta to offer services such as Contract Development and Manufacturing products.
Senores IPO Details
| IPO Date | December 20, 2024 to December 24, 2024 |
| Listing Date | — |
| Face Value | ₹10 per share |
| Price Band | ₹372 to ₹391 per share |
| Minimum Investment | ₹14,136 |
| Lot Size | 38 Shares |
| Total Issue Size | 1,48,87,723 shares |
| Fresh Issue | 1,27,87,723 shares |
| Offer for Sale | 21,00,000 shares of ₹10 |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,32,65,865 shares |
| Share Holding Post Issue | 4,60,53,588 shares |
This company has a strong presence in growing markets, operating in 43 countries. The company has formed partnerships in well-regulated markets such as the US, Canada, and the UK, working with both global and Indian pharmaceutical companies. With time passing its finances improved very well, in 2023, its profit was just 8.43 Cr whereas in 2024 it became 32.71. The company’s fundamentals are very strong which supports it for further growth.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2024 | 365 | 420 |
The company does business with the US, Canada, and the UK through agreements with other pharmaceutical companies for marketing and distribution. It has launched a range of products in key areas like antifungals, antibiotics, antibacterial, and blood-related treatments. The company is well-established in hospitals across India, working with distributors and directly with hospitals too. As the company doing well, its stock will do the same in the stock market, so by 2025, its stock price target will be ₹540, as per our expert’s analysis.
By our expert’s prediction, its stock price will be between ₹480 to ₹540 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 408 | 540 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 408 | 422 |
| February | 415 | 428 |
| March | 421 | 432 |
| April | 426 | 445 |
| May | 431 | 456 |
| June | 443 | 465 |
| July | 458 | 478 |
| August | 462 | 489 |
| September | 485 | 508 |
| October | 501 | 519 |
| November | 514 | 533 |
| December | 531 | 540 |
It develops and manufactures a variety of pharmaceutical products mainly for regulated markets like the US, Canada, and the UK. The company has launched a range of products and established strong partnerships with distributors and hospitals across India. Also, it operates three dedicated R&D facilities in India and the US and serves 43 countries in emerging markets, manufacturing critical care injectables and active pharmaceutical ingredients. The company doing great business in India as well as internationally. In 2026, its stock price target would be ₹680 as per our analysis.
By our prediction, its stock price target would be between ₹531 to ₹680 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 531 | 680 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 531 | 547 |
| February | 538 | 559 |
| March | 550 | 576 |
| April | 568 | 587 |
| May | 579 | 594 |
| June | 586 | 618 |
| July | 603 | 623 |
| August | 617 | 646 |
| September | 628 | 658 |
| October | 637 | 663 |
| November | 653 | 674 |
| December | 667 | 680 |
The company uses data, research, and experienced management to find unique and less common molecules for new products in both regulated and emerging markets. The company focuses on developing high-quality, complex medicines. Its strong R&D efforts have led to a wide range of products in different forms and medical areas. It has partnerships with both foreign and Indian pharmaceutical companies in markets like the US, Canada, and the UK. It had a strong presence in the global market, making it an attractive company for investors. In 2030, its stock price target would be ₹1126 as per our prediction.
So, by 2030, its stock price will be between ₹950 to ₹1126, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 1050 | 1226 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1050 | 1069 |
| February | 1063 | 1088 |
| March | 1073 | 1098 |
| April | 1090 | 1123 |
| May | 1018 | 1130 |
| June | 1123 | 1138 |
| July | 1130 | 1147 |
| August | 1139 | 1168 |
| September | 1156 | 1179 |
| October | 1163 | 1190 |
| November | 1185 | 1213 |
| December | 1208 | 1226 |
It manufactures critical care injectables and active pharmaceutical ingredients, which are very important in producing medicines used in hospitals and health care. The company focuses heavily on research and development, which enables it to take products from concept to successful launch. Its strength is in managing the entire product development process smoothly, making sure safe, high-quality medicines are delivered to fulfil healthcare needs around the world. So by 2040, its stock price target would be ₹2431 as per our prediction.
By our analysis, its stock price would be between ₹2011 to ₹2431 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 2011 | 2431 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2011 | 2043 |
| February | 2030 | 2067 |
| March | 2051 | 2078 |
| April | 2065 | 2096 |
| May | 2073 | 2123 |
| June | 2102 | 2156 |
| July | 2141 | 2186 |
| August | 2167 | 2215 |
| September | 2200 | 2267 |
| October | 2248 | 2328 |
| November | 2293 | 2388 |
| December | 2367 | 2431 |
The company has formed long-term marketing agreements with major pharmaceutical companies operating in global markets. The company builds long-term relationships as products move from clinical trials to commercial production. This leads to sustained business and steady revenue. The company offers a range of services, including development support, analytical testing, project management, manufacturing, and regulatory assistance. This approach helps the company use its manufacturing capacity efficiently and cost-effectively to support product development. Apart from this, they invest a good amount of money in the research and development team for further growth. So, by 2050, its stock price target would be ₹5244 as per our expert’s analysis.
According to our experts, its stock price will be between ₹4667 to ₹5244 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 4667 | 5244 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 4667 | 4690 |
| February | 4683 | 4756 |
| March | 4740 | 4834 |
| April | 4790 | 4856 |
| May | 4811 | 4878 |
| June | 4835 | 4936 |
| July | 4890 | 5047 |
| August | 4968 | 5073 |
| September | 5028 | 5123 |
| October | 5076 | 5158 |
| November | 5132 | 5218 |
| December | 5190 | 5244 |
Should I buy Senores stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 408 | 540 |
| 2026 | 531 | 680 |
| 2030 | 1050 | 1226 |
| 2040 | 2011 | 2431 |
| 2050 | 4667 | 5244 |
It looks like a good investment due to its strong presence in the global markets. The company focuses on developing innovative and complex medicines, through strong research and experiments. Their effective medicine is always in demand globally. Also, the company’s finances are improving by the year. So for long-term investment, you can take a chance on this stock, but you should always remember the stock market risks.
Senores Pharmaceuticals Ltd earning results (Financials)
| Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 14 | 35 | 215 |
| Expenses + | 12 | 23 | 173 |
| Operating Profit | 2 | 13 | 42 |
| OPM % | 14% | 36% | 19% |
| Other Income + | 0 | 4 | 3 |
| Interest | 1 | 2 | 9 |
| Depreciation | 1 | 2 | 10 |
| Profit before tax | 1 | 12 | 25 |
| Tax % | 13% | 32% | -31% |
| Net Profit + | 1 | 8 | 33 |
| EPS in Rs | |||
| Dividend Payout % | 0% | 0% | 0% |
Is Senore stock good to buy? (Bull case & bear case)
Bull Case:
- It operates in both regulated markets (US, Canada, UK) and 43 emerging markets, offering growth potential.
- This company develops complex, underpenetrated pharmaceutical products, giving it a competitive edge.
- Long-term relationships with major pharmaceutical companies provide stable revenue.
- It generates income from licensing, profit-sharing, and CDMO services, reducing dependency on one source.
Bear Case:
- Operating in highly regulated markets, it faces delays in delivering products.
- The pharmaceutical industry is very competitive.
- The company has A high debtor of 191 days.
Senores IPO Promoter Holding
The promoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
| Share Holding Pre Issue | 71.10% |
| Share Holding Post Issue | — |
Objects of the Issue (Senores IPO Objectives)
- Investment in the subsidiary Havix Group, Inc. to support the setup of a manufacturing facility for sterile injections at the Atlanta location.
- Repayment or pre-payment, either fully or partially, of certain company borrowings.
- Investment in Havix to help repay or pre-pay its borrowings.
- Providing funds for the company’s working capital needs.
- Investment in subsidiaries Senores Pharmaceuticals Inc. and Ratnatris Pharmaceutical Private Limited to meet their working capital requirements.
- Funding growth through acquisitions, strategic initiatives, and general corporate purposes.
Senores IPO GMP
The grey market premium is the price at which an IPO is traded in an unofficial market before it is officially listed on the stock exchange. The GMP gives an idea of how the IPO might perform on its listing day. A positive GMP suggests the IPO could be profitable, while a negative GMP indicates it may be offered at a discount. Senores Pharmaceuticals IPO last GMP is ₹220, as of Dec 23rd 2024 04:28 PM. With a price band of 391.00, Its IPO’s estimated listing price is ₹611. The expected percentage gain/loss per share is 56.27%.
Conclusion
The company speciality in complex, specialty drugs and has solid partnerships with major pharmaceutical companies, offering a diversified revenue. Its strong R&D capabilities and efficient manufacturing processes position it for long-term success. In this article, we have explained this company very well, so for a better overview please read the whole article.
